Martin Stern
Overview
Explore the profile of Martin Stern including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
163
Citations
3261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benzekry S, Karlsen M, Bigarre C, El Kaoutari A, Gomes B, Stern M, et al.
Clin Pharmacol Ther
. 2024 Jul;
116(4):1110-1120.
PMID: 39001619
Existing survival prediction models rely only on baseline or tumor kinetics data and lack machine learning integration. We introduce a novel kinetics-machine learning (kML) model that integrates baseline markers, tumor...
2.
Caudell D, Dugan G, Babitzki G, Schubert C, Braendli-Baiocco A, Wasserman K, et al.
J Leukoc Biol
. 2024 Feb;
115(6):1084-1093.
PMID: 38372596
The cell surface molecule CD40 is a member of the tumor necrosis factor receptor superfamily and is broadly expressed by immune cells including B cells, dendritic cells, and monocytes, as...
3.
Ribba B, Roller A, Helms H, Stern M, Bleul C
Front Pharmacol
. 2023 Mar;
13:1058220.
PMID: 36968790
To support further development of model-informed drug development approaches leveraging circulating tumor DNA (ctDNA), we performed an exploratory analysis of the relationships between treatment-induced changes to ctDNA levels, clinical response...
4.
Leclercq G, Haegel H, Toso A, Zimmermann T, Green L, Steinhoff N, et al.
J Immunother Cancer
. 2022 Jan;
10(1).
PMID: 35064010
Background: T cell engaging therapies, like chimeric antigen receptor T cells and T cell bispecific antibodies (TCBs), efficiently redirect T cells towards tumor cells, facilitating the formation of a cytotoxic...
5.
Byrne K, Betts C, Mick R, Sivagnanam S, Bajor D, Laheru D, et al.
Clin Cancer Res
. 2021 Jun;
27(16):4574-4586.
PMID: 34112709
Purpose: CD40 activation is a novel clinical opportunity for cancer immunotherapy. Despite numerous active clinical trials with agonistic CD40 monoclonal antibodies (mAb), biological effects and treatment-related modulation of the tumor...
6.
Turck D, Bresson J, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, et al.
EFSA J
. 2021 Apr;
19(3):e06557.
PMID: 33791041
[Table: see text] Following the adoption of Regulation (EU) 2015/2283 on Novel Foods, the European Commission requested EFSA to develop a scientific and technical guidance for the preparation and submission...
7.
Turck D, Bresson J, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, et al.
EFSA J
. 2021 Apr;
19(3):e06556.
PMID: 33791040
[Table: see text] Following a request from the European Commission, EFSA was asked to provide scientific and technical guidance for the preparation and presentation of a dossierfor evaluation of an...
8.
Nutrition , Nda A, Turck D, Bresson J, Burlingame B, Dean T, et al.
EFSA J
. 2021 Apr;
19(3):e06555.
PMID: 33791039
[Table: see text] Following the adoption of Regulation (EU) 2015/2283 on novel foods, the European Commission requested EFSA develop scientific and technical guidance for the preparation and submission of applications...
9.
Tschan-Plessl A, Kalberer C, Wieboldt R, Stern M, Siegler U, Wodnar-Filipowicz A, et al.
Cytotherapy
. 2020 Dec;
23(4):329-338.
PMID: 33268029
Background Aims: To investigate the feasibility and safety of haploidentical natural killer (NK) cell infusions as consolidation immunotherapy after autologous stem cell transplant (ASCT) in patients with plasma cell myeloma....
10.
Turck D, Bresson J, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, et al.
EFSA J
. 2020 Jul;
16(8):e05365.
PMID: 32626014
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to revise the tolerable upper intake level (UL) for vitamin D for...